ArticleThe Journal of cell biology2003
Alpha(v)beta3 integrin expression up-regulates cdc2, which modulates cell migration.
Article in The Journal of cell biology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 123 citations in OpenAlex.
- Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.Investigational new drugs · 2012Trial
- In silico framework about prediction of collagen-derived matrikine generation and its ligand function binding to integrin [Formula: see text] for malignancy of colon cancer.In silico pharmacology · 2025Article
- Glucocorticoid receptor-induced non-muscle caldesmon regulates metastasis in castration-resistant prostate cancer.Oncogenesis · 2023Article
- Genetically Engineered Hepatitis C Virus-like Particles (HCV-LPs) Tagged with SP94 Peptide to Acquire Selectivity to Liver Cancer Cells via Grp78.Current issues in molecular biology · 2022Article
- Integrin α2 and β1 Cross-Communication with mTOR/AKT and the CDK-Cyclin Axis in Hepatocellular Carcinoma Cells.Cancers · 2022Article
- Notch controls the cell cycle to define leader versus follower identities during collective cell migration.eLife · 2022Article
- Botulinum Toxin and Neuronal Regeneration after Traumatic Injury of Central and Peripheral Nervous System.Toxins · 2020Review
- Article
- αMolecular cancer research : MCR · 2019Article
- Modifications of disulfide bonds in breast cancer cell migration and invasiveness.American journal of cancer research · 2019Article
- Cell adhesion is regulated by CDK1 during the cell cycle.The Journal of cell biology · 2018Article
- αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor.Cancer research · 2016Article
- Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET.Oncotarget · 2016Article
- Knockdown of PFTK1 Inhibits the Migration of Glioma Cells.Journal of molecular neuroscience : MN · 2015Article
- Defining the phospho-adhesome through the phosphoproteomic analysis of integrin signalling.Nature communications · 2015Article
- Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors.Cell cycle (Georgetown, Tex.) · 2015Review
- A naturally derived small molecule disrupts ligand-dependent and ligand-independent androgen receptor signaling in human prostate cancer cells.Molecular cancer therapeutics · 2014Article
- Article
- Article
- Quantitative imaging of epithelial cell scattering identifies specific inhibitors of cell motility and cell-cell dissociation.Science signaling · 2012Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
The alphavbeta3 integrin has been shown to promote cell migration through activation of intracellular signaling pathways. We describe here a novel pathway that modulates cell migration and that is activated by alphavbeta3 and, as downstream effector, by cdc2 (cdk1). We report that alphavbeta3 expression in LNCaP (beta3-LNCaP) prostate cancer cells causes increased cdc2 mRNA levels as evaluated by gene expression analysis, and increased cdc2 protein and kinase activity levels. We provide three lines of evidence that increased levels of cdc2 contribute to a motile phenotype on integrin ligands in different cell types. First, increased levels of cdc2 correlate with more motile phenotypes of cancer cells. Second, ectopic expression of cdc2 increases cell migration, whereas expression of dominant-negative cdc2 inhibits migration. Third, cdc2 inhibitors reduce cell migration without affecting cell adhesion. We also show that cdc2 increases cell migration via specific association with cyclin B2, and we unravel a novel pathway of cell motility that involves, downstream of cdc2, caldesmon. cdc2 and caldesmon are shown here to localize in membrane ruffles in motile cells. These results show that cdc2 is a downstream effector of the alphavbeta3 integrin, and that it promotes cell migration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.